Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2011-05-02 AGM Information
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
CONTINUED ANNUAL GENERAL MEETING OF Karo Bio AB (PUBL)
AGM Information Classification · 99% confidence The document explicitly discusses the 'CONTINUED ANNUAL GENERAL MEETING OF KARO BIO AB (PUBL)'. It details the adjournment of the AGM, the rescheduled date (May 4th, 2011), logistical details (location, proxy rules), and presents a proposed agenda for the resumed meeting, including items like 'Election of board members' and 'Resolution as to principles for remuneration'. This content is directly related to the proceedings and materials of an Annual General Meeting. Therefore, the classification is AGM-R (AGM Information). The document length is moderate, but the content is the meeting material itself, not just an announcement of a report.
2011-05-02 English
THE ANNUAL GENERAL MEETING OF KARO BIO AB (PUBL) ADJOURNED
AGM Information Classification · 99% confidence The document explicitly discusses the proceedings and resolutions passed during 'THE ANNUAL GENERAL MEETING OF KARO BIO AB (PUBL)'. Key elements include the adjournment of the meeting, resolutions on profit allocation, discharge from liability, and decisions regarding board remuneration. This content directly relates to the formal business conducted at an AGM. Therefore, the classification is AGM-R (AGM Information). The document is a report/summary of the meeting, not just an announcement of a future meeting or a proxy solicitation.
2011-04-28 English
ÅRSSTÄMMAN I KARO BIO AB (PUBL) AJOURNERAD
AGM Information Classification · 98% confidence The document text is titled 'ÅRSSTÄMMAN I KARO BIO AB (PUBL) AJOURNERAD' (Annual General Meeting in Karo Bio AB (publ) Adjourned) and details decisions made during the Annual General Meeting (AGM), such as the adjournment, voting on remuneration, and approval of financial statements/discharge of directors. The content directly relates to the proceedings and decisions of the AGM. This aligns perfectly with the definition for AGM Information (AGM-R). Although it is a press release format, the core subject matter is the AGM itself, making AGM-R more specific than RPA or RNS.
2011-04-28 Swedish
Interim / Quarterly Report 2011
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January-March 2011. It contains comprehensive financial data, including income statements, cash flow, and balance sheet summaries, as well as detailed management commentary, project updates, and operational highlights. It is not a mere announcement of a report, but the report itself, containing substantive financial analysis and data for a period shorter than a full fiscal year. Q1 2011
2011-04-27 Swedish
Interim / Quarterly Report 2011
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT JANUARY–MARCH 2011' and contains comprehensive financial data, including net sales, net loss, earnings per share, cash flow, and balance sheet information for the specified period. It also includes management commentary (CEO's comments) and project status updates. It is a full quarterly financial report, not an announcement or a summary, and therefore fits the definition of an Interim/Quarterly Report (IR). Q1 2011
2011-04-27 English
KARO BIO OCH ALKEM LABORATORIES LTD INGÅR SAMARBETE FÖR UTVECKLING AV EPROTIROME
Regulatory Filings Classification · 95% confidence The document is a press release dated April 26, 2011, announcing a collaboration and licensing agreement between Karo Bio and Alkem Laboratories regarding the drug eprotirome. It details the terms of the agreement, clinical trial plans (Phase III in India), financial implications (reduction in Karo Bio's investment), and background information on both companies. This type of announcement, detailing a significant business transaction (licensing/partnership) that impacts future commercialization and development, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or specific corporate actions (like DIV, SHA, POS). It is a general business update concerning strategic development and commercial rights. Since it is a formal announcement of a significant business event, and it doesn't fit the definitions for M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate general category for a significant, non-standard regulatory announcement is 'Regulatory Filings' (RNS), which serves as a broad category for important corporate news releases that aren't covered by more specific codes. Given the content is a strategic business deal announcement, RNS is the best fit among the provided options.
2011-04-26 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.